<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335255</url>
  </required_header>
  <id_info>
    <org_study_id>NFTC 1409-1722</org_study_id>
    <nct_id>NCT02335255</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® (Naftifine Hydrochloride) Gel 2% in Patients With Tinea Pedis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of the test formulation Naftifine Hydrochloride Gel 2% to&#xD;
      Naftin® (Naftifine Hydrochloride) Gel 2%&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of the test formulation&#xD;
      Naftifine Hydrochloride Gel 2% to Naftin® (Naftifine Hydrochloride) Gel 2% in a six week&#xD;
      study (four weeks after the end of two week treatment) in patients with tinea pedis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2014</start_date>
  <completion_date type="Actual">May 15, 2018</completion_date>
  <primary_completion_date type="Actual">May 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic cure after end of treatment</measure>
    <time_frame>Study day 38-46</time_frame>
    <description>The proportion of subjects with therapeutic cure, defined as both mycological cure and clinical cure, at the test-of-cure visit conducted four weeks after the end of treatment (study day 38-46).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1519</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Naftifine Hydrochloride Gel 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naftifine Hydrochloride Gel 2% (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naftin® Gel 2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naftin® (Naftifine Hydrochloride) Gel 2% (Merz Pharmaceuticals, LLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Topical Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Topical Gel (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftifine Hydrochloride Gel 2%</intervention_name>
    <description>Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.</description>
    <arm_group_label>Naftifine Hydrochloride Gel 2%</arm_group_label>
    <other_name>Naftifine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftin® Gel 2%</intervention_name>
    <description>Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.</description>
    <arm_group_label>Naftin® Gel 2%</arm_group_label>
    <other_name>Naftifine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Topical Gel</intervention_name>
    <description>Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.</description>
    <arm_group_label>Placebo Topical Gel</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating females 18 years of age or older.&#xD;
&#xD;
          -  The sum of the clinical signs and symptoms scores of the target lesion is at least 4,&#xD;
             including a minimum score of at least 2 for erythema and a minimum score of 2 for&#xD;
             either scaling or pruritus.&#xD;
&#xD;
          -  Clinical diagnosis of interdigital tinea pedis with lesions localized to the&#xD;
             interdigital spaces or predominantly interdigital, but may extend to other areas of&#xD;
             the foot.&#xD;
&#xD;
          -  The presence of interdigital tinea pedis infection, confirmed by the observation of&#xD;
             segmented fungal hyphae during a microscopic potassium hydroxide wet mount&#xD;
             preparation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant, lactating or planning to become pregnant during the study&#xD;
             period.&#xD;
&#xD;
          -  Use of antipruritics, including antihistamines within 72 hours prior to baseline&#xD;
             visit.&#xD;
&#xD;
          -  Use of topical corticosteroids, antibiotics or antifungal therapies within 2 weeks&#xD;
             prior to baseline visit.&#xD;
&#xD;
          -  Use of systemic corticosteroids, antibiotics or antifungal therapies within 1 month&#xD;
             prior to baseline visit.&#xD;
&#xD;
          -  Use of oral Terbinafine or Itraconazole within 2 months prior to baseline visit.&#xD;
&#xD;
          -  Use of immunosuppressive medication or radiation therapy within 3 months prior to&#xD;
             baseline visit.&#xD;
&#xD;
          -  Any known hypersensitivity to Naftifine Hydrochloride, or any component of the&#xD;
             formulation.&#xD;
&#xD;
          -  Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.&#xD;
&#xD;
          -  History of significant or current evidence of chronic infectious disease, system&#xD;
             disorder, organ disorder, or other medical condition that would place patient at undue&#xD;
             risk by participation or could jeopardize the integrity of the study evaluations.&#xD;
&#xD;
          -  Evidence of any concurrent dermatophytic infection of the toe nails or dermatological&#xD;
             condition of the foot that may interfere with the investigator's evaluation of tinea&#xD;
             pedis.&#xD;
&#xD;
          -  Patients with a past history of dermatophyte infections with a lack of response to&#xD;
             antifungal therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catawba Research</last_name>
    <role>Study Chair</role>
    <affiliation>http://catawbaresearch.com/contact/</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2015</study_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naftifine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

